Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT17: Erlotinib vs intercalated erlotinib + cisplatin + pemetrexed for EGFR-mutated advanced NSCLC
2013-004303-39Phase 3Completed
- Sponsor
- NVALT
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NVALT. Primary endpoint: Progression-free survival. Started Nov 2013; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-004303-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004303-39.